Cefepime






101 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 1424521 In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae. Diagn Microbiol Infect Dis 1992 Sep-Oct 3
2 2499250 Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels. Antimicrob Agents Chemother 1989 Apr 5
3 8150770 Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. The Canadian Antimicrobial Resistance Study Group. J Antimicrob Chemother 1993 Nov 1
4 8738850 Diffusion of 3-quaternary ammonium cephem antibiotics into cerebrospinal fluid of patients with bacterial meningitis. J Chemother 1996 Feb 3
5 10052697 Quantitative determination of cefepime in plasma and vitreous fluid by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999 Jan 22 1
6 10636865 beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 2000 Jan 21 3
7 10668589 In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999 Dec 1
8 10722487 Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000 Apr 1
9 10854806 In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. Int J Antimicrob Agents 2000 Jul 1
10 11105137 Antimicrobial Susceptibility of Klebsiella pneumoniae Producing Extended-Spectrum beta-lactamase (ESBL) Isolated in Hospitals in Brazil. Braz J Infect Dis 1997 Aug 3
11 11996691 Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan. Emerg Infect Dis 2002 May 1
12 12482126 Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia. Med Oncol 2002 2
13 12507831 Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Agents 2003 Jan 2
14 12574281 Occurrence of extended-spectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases. J Clin Microbiol 2003 Feb 3
15 12615876 Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother 2003 Mar 1
16 12702671 Experimental prediction of the natural evolution of antibiotic resistance. Genetics 2003 Apr 1
17 12730001 Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003 Apr 1
18 14628571 [Characteristics and clinical value of extended-spectrum beta-lactamases]. Antibiot Khimioter 2003 1
19 15150168 Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection. J Antimicrob Chemother 2004 Jul 1
20 15155182 Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother 2004 Jun 1
21 15728940 Experimental prediction of the evolution of ceftazidime resistance in the CTX-M-2 extended-spectrum beta-lactamase. Antimicrob Agents Chemother 2005 Mar 1
22 15847220 [Susceptibility of ESBL-producing Escherichia coli and Klebsiella pneumoniae to various antibacterial agents]. Jpn J Antibiot 2005 Feb 1
23 16230218 Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect 2005 Oct 5
24 16290025 Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagn Microbiol Infect Dis 2006 Jan 1
25 16440125 In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J Microbiol Immunol Infect 2006 Feb 2
26 16544267 Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006 Apr 15 3
27 16930923 Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007 Jan 1
28 16930925 Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis 2007 Feb 1
29 17084784 Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagn Microbiol Infect Dis 2006 Nov 4
30 18294108 In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Pharmacotherapy 2008 Mar 2
31 18452417 Population pharmacokinetics of cefepime in neonates with severe nosocomial infections. J Clin Pharm Ther 2008 Jun 1
32 18519727 Restoration of susceptibility of intracellular methicillin-resistant Staphylococcus aureus to beta-lactams: comparison of strains, cells, and antibiotics. Antimicrob Agents Chemother 2008 Aug 1
33 18559652 Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. Antimicrob Agents Chemother 2008 Aug 1
34 18567754 Acute administration of cefepime lowers L-carnitine concentrations in early lactation stage rat milk. J Nutr 2008 Jul 1
35 18658192 Antimicrobial activity of cefepime and rifampicin in cerebrospinal fluid in vitro. J Antimicrob Chemother 2008 Nov 1
36 18772158 First occurrence of KPC-2-possessing Klebsiella pneumoniae in a Greek hospital and recommendation for detection with boronic acid disc tests. J Antimicrob Chemother 2008 Dec 1
37 18781908 Fixed dose combination of cefepime plus amikacin prevent oxidative stress in liver of Mus musculus mice. Curr Clin Pharmacol 2008 Sep 2
38 19414578 Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. Antimicrob Agents Chemother 2009 Jul 1
39 20130375 Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria. J Infect Dev Ctries 2009 Nov 21 5
40 20194701 Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan. Antimicrob Agents Chemother 2010 May 1
41 21149619 A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2011 Mar 1
42 21393128 Cefepime effectiveness in Gram-negative bloodstream infections. J Antimicrob Chemother 2011 May 1
43 21742679 False extended-spectrum {beta}-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins. J Antimicrob Chemother 2011 Sep 2
44 21767713 Characterization of a novel extended-spectrum β-lactamase phenotype from OXA-1 expression in Salmonella Typhimurium strains from Africa and Ireland. Diagn Microbiol Infect Dis 2011 Aug 1
45 21986835 Cefepime-associated thrombocytopenia in a critically ill patient. Int J Clin Pharm 2011 Dec 3
46 22005996 Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012 Jan 2
47 22041508 In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012 Jan 1
48 22290945 Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother 2012 Apr 1
49 22298349 Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports. J Antimicrob Chemother 2012 May 1
50 22345386 In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to cefotaxime, ceftazidime, cefepime and aztreonam. J Antimicrob Chemother 2012 Jun 1